Key Dates
- Postal Ballot Notice dispatched: July 18, 2026
- Remote e-voting period: July 19, 2026 (9:00 AM IST) to August 17, 2026 (5:00 PM IST)
- Cut-off date for shareholder eligibility: July 10, 2026
- Results announcement: On or before August 19, 2026
Resolutions for Shareholder Approval
Item No. 1: Re-appointment of Mr. Priyavrat Bhartia as Managing Director
- Proposed term: June 1, 2026 to May 31, 2029 (3 years)
- Remuneration: Up to ₹7,50,00,000 per annum (salary and perquisites)
- DIN: 00020603
- Current term expires: May 31, 2026
- Ratio to median employee remuneration: 24.99:1 (as of March 31, 2026)
- Board meeting attendance: 4 out of 6 meetings in FY 2025-26
Item No. 2: Re-appointment of Mr. Arjun Shanker Bhartia as Joint Managing Director
- Proposed term: June 1, 2026 to May 31, 2029 (3 years)
- Remuneration: Up to ₹7,50,00,000 per annum (salary and perquisites)
- DIN: 03019690
- Current term expires: May 31, 2026
- Ratio to median employee remuneration: 24.99:1 (as of March 31, 2026)
- Board meeting attendance: 6 out of 6 meetings in FY 2025-26
Remuneration Details
Both directors will receive:
- Salary and perquisites up to ₹7.5 crore annually
- Perquisites include: furnished/non-furnished accommodation or HRA, electricity, LTC for self and family, group mediclaim, life insurance, accidental insurance, home security, international mediclaim, entertainment expenses reimbursement, company-maintained car, telephone
- Company's contribution to Provident Fund (non-taxable portion), gratuity, and leave encashment excluded from remuneration computation
- Conveyance facilities, communication facilities, club membership fees reimbursement
- 3-month notice period for termination
Financial Performance Context
Standalone Financials (FY 2025-26)
- Paid-up Capital: ₹159 million
- Reserves (excluding revaluation): ₹22,964 million
- Total Revenue from operations: ₹2,635 million
- Total Expenses: ₹2,280 million
- Profit before Tax: ₹292 million
- Tax Expenses: ₹93 million
- Profit after Tax: ₹632 million
Consolidated Financials (FY 2025-26)
- Paid-up Capital: ₹158 million
- Reserves (excluding revaluation): ₹70,770 million
- Total Revenue: ₹82,796 million
- Total Expenses: ₹76,720 million
- Profit before Tax: ₹6,141 million
- Tax Expenses: ₹2,166 million
- Profit after Tax: ₹3,975 million
Business Context
Jubilant Pharmova is an integrated global pharmaceutical company engaged in:
- Radiopharma (45 radiopharmacies in USA)
- Allergy Immunotherapy (USA, Canada, Europe, Australia)
- Contract Development and Manufacturing of sterile injectables (USA and Canada facilities)
- Contract Research Development and Manufacturing (3 research centers in India and France)
- Generics (solid dosage formulations)
- Proprietary Novel Drugs (oncology and auto-immune disorders)
Regulatory Requirements
The special resolutions are required because:
- Remuneration may exceed 5% of net profits for each director
- Aggregate remuneration may exceed 10% of net profits for managing/whole-time directors
- Both directors are promoter group members
- Standalone profits are considered inadequate for remuneration limits
Voting Process
- E-voting through NSDL platform
- Documents available for inspection at registered office in Bhartiagram, Gajraula, District Amroha, Uttar Pradesh-244223
- Scrutinizer: Mr. Rupinder Singh Bhatia, Practicing Company Secretary
- Results will be displayed on company website, NSDL website, and notified to BSE and NSE
Additional Information
- Both directors are not entitled to stock options under Jubilant Pharmova Employees Stock Option Plan 2018
- Company confirms no default in payment of dues to any bank, financial institution, or secured creditors
- API business transferred to Jubilant Biosys Limited (wholly-owned subsidiary) in FY 2025-26, classified as discontinued operation in standalone financials